Phase 1 Acute Lymphocytic Leukemia Clinical Trials
12 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–12 of 12 trials
Recruiting
Phase 1
Pilot Imaging Study of Leukemia
Acute Myeloid LeukemiaMyelomaAcute Lymphocytic Leukemia+1 more
University of Oklahoma60 enrolled3 locationsNCT03633955
Recruiting
Phase 1Phase 2
Phase Ib/II Study Assessing the Clinical Activity and Safety of Brexucabtagene Autoleucel as a Consolidation in Patients With Relapsed/Refractory (R/R) and Newly Diagnosed B-cell Acute Lymphocytic Leukemia (ALL) Post Cytoreduction With Mini-HCVD-inotuzumab-blinatumomab/HCVAD-inotuzumab-blinatumomab
Relapsed/RefractoryB-cell Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center40 enrolled1 locationNCT06287229
Recruiting
Phase 1Phase 2
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors
Solid TumorsAcute Lymphoblastic LeukemiaAcute Myeloid Leukemia+6 more
Incyte Biosciences International Sàrl70 enrolled23 locationsNCT03934372
Recruiting
Phase 1Phase 2
TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Acute Lymphocytic Leukemia
Chinese PLA General Hospital30 enrolled6 locationsNCT06481735
Recruiting
Phase 1Phase 2
CD19/CD22 Bicistronic Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies
Acute Lymphoblastic LeukemiaAcute Lymphocytic LeukemiaB-Non Hodgkin Lymphoma+2 more
National Cancer Institute (NCI)126 enrolled1 locationNCT05442515
Recruiting
Phase 1Phase 2
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT06316856
Recruiting
Phase 1Phase 2
A Study of CTD402 in T-ALL/LBL Patients
Lymphoma, LymphoblasticAcute Lymphocytic Leukemia Refractory
BIOHENG THERAPEUTICS US LLC54 enrolled8 locationsNCT07070219
Recruiting
Phase 1Phase 2
Tafasitamab (MOR00208) in Pediatric Patients With Relapsed or Refractory Acute B Lineage Leukemia
ALL, Childhood B-CellAcute Lymphoid Leukemia RelapseAcute Lymphocytic Leukemia Refractory
University Hospital Tuebingen20 enrolled11 locationsNCT05366218
Recruiting
Phase 1
Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN)
Chronic Lymphocytic LeukemiaNon-Hodgkin LymphomaAcute Lymphocytic Leukemia
Baylor College of Medicine64 enrolled2 locationsNCT01853631
Recruiting
Phase 1Phase 2
A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Refractory/Relapsed T Lymphocyte Malignancies
Acute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoblastic LeukemiaT-cell Malignancies+1 more
Beijing GoBroad Hospital54 enrolled4 locationsNCT07070323
Recruiting
Phase 1Phase 2
BCOR and ZC3H12 Genes Knock-out CD19-targeting CAR-T Cell Therapy in r/r B-ALL
Acute Lymphocytic Leukemia
Chinese PLA General Hospital30 enrolled2 locationsNCT07008885
Recruiting
Phase 1Phase 2
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
Acute Lymphocytic Leukemia
Leland Metheny44 enrolled7 locationsNCT03104491